Importantly, the aggressive top-down tumours that emerge, following Tgfbr1 deletion, exhibit deregulated MAPK signalling and are therefore sensitive to MEK1/2 inhibition, providing an opportunity for early therapeutic intervention [285]. This evidence concerns the gene TGFBR1 and neoplasm.